Trumenba (meningococcal B vaccine) / Pfizer 
Welcome,         Profile    Billing    Logout  
 12 Diseases   4 Trials   4 Trials   240 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trumenba (meningococcal B vaccine) / Pfizer
2017-004609-42: Be on the TEAM: TEenagers Against Meningitis

Not yet recruiting
4
24000
Europe
Bexsero, Trumenba, Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, Bexsero, Trumenba
Clinical Trials and Research Governance (CTRG), University of Oxford, National Institute of Health Research, Pfizer Ltd
Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage of meningococci., Bacterial colonisation of the mouth and throat with a germ called meningococcus. The ability of vaccines to reduce the rates of colonisation with this germ., Body processes [G] - Immune system processes [G12]
 
 
NCT04893811 / 2018-002588-24: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Completed
4
53
Europe, RoW
Trumenba
Pfizer
Meningococcal Vaccine
09/23
09/23
2019-000924-17: Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase III, évaluant l'immunogénicité et la tolérance de trois stratégies vaccinales contre le méningocoque B chez des patients présentant une asplénie

Not yet recruiting
3
84
Europe
Solution for injection, Bexsero®, Trumenba®
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DGOS
asplenic patients at risk for invasive meningococcal disease Patients splénectomisés à risque d'infection à meningocoque B, asplenic patients patients splénectomisés, Body processes [G] - Immune system processes [G12]
 
 
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
2013-002137-38: A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 11 to < 18 years of age.

 
2
2500
NA
Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,
Pfizer Inc, Pfizer Inc
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
 
 
2013-002145-11: A clinical study evaluating the safety, tolerability, and immune response to MCV4 and TDAP vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 10 to < 13 years of age.

 
2
2625
NA
Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,
Pfizer Inc, Pfizer Inc
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
 
 
NCT06128733: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Active, not recruiting
1/2
1220
US
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadFi®, Meningococcal group B vaccine, Bexsero®, Trumenba®, Sanofi MenB, Menveo®, Placebo, MenABCYW conjugate vaccine, PENBRAYATM
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
06/25
06/25
2023-000924-13: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Not yet recruiting
1/2
1120
US
MenQuadfi, Bexsero, Trumenba, Menveo, 554, Suspension for injection, Solution for injection in vial, Suspension for injection in pre-filled syringe, Powder and solvent for solution for injection, MenQuadfi, Bexsero, Trumenba, MENVEO
Sanofi Pasteur Inc., Sanofi Pasteur Inc.
Bacterial infections and mycoses, Bacterial infections and mycoses, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04825223: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Terminated
1
576
US
Multicomponent Meningococcal B Vaccine, Trumenba®, Meningococcal Group B Vaccine MenB, MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Bexsero®, Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine, MenQuadfi™
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
07/22
07/22
NCT05873751: A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed
N/A
1307378
US
Trumenba Vaccine, MenACWY Vaccine
Pfizer
Gonorrhea, Chlamydia, Meningococcal Vaccines
03/24
03/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trumenba (meningococcal B vaccine) / Pfizer
2017-004609-42: Be on the TEAM: TEenagers Against Meningitis

Not yet recruiting
4
24000
Europe
Bexsero, Trumenba, Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, Bexsero, Trumenba
Clinical Trials and Research Governance (CTRG), University of Oxford, National Institute of Health Research, Pfizer Ltd
Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage of meningococci., Bacterial colonisation of the mouth and throat with a germ called meningococcus. The ability of vaccines to reduce the rates of colonisation with this germ., Body processes [G] - Immune system processes [G12]
 
 
NCT04893811 / 2018-002588-24: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Completed
4
53
Europe, RoW
Trumenba
Pfizer
Meningococcal Vaccine
09/23
09/23
2019-000924-17: Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase III, évaluant l'immunogénicité et la tolérance de trois stratégies vaccinales contre le méningocoque B chez des patients présentant une asplénie

Not yet recruiting
3
84
Europe
Solution for injection, Bexsero®, Trumenba®
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DGOS
asplenic patients at risk for invasive meningococcal disease Patients splénectomisés à risque d'infection à meningocoque B, asplenic patients patients splénectomisés, Body processes [G] - Immune system processes [G12]
 
 
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
2013-002137-38: A clinical study evaluating the safety, tolerability, and immune response to HPV vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 11 to < 18 years of age.

 
2
2500
NA
Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,
Pfizer Inc, Pfizer Inc
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
 
 
2013-002145-11: A clinical study evaluating the safety, tolerability, and immune response to MCV4 and TDAP vaccine given together with Bivalent RLP2086 vaccine in healthy subjects ≥ 10 to < 13 years of age.

 
2
2625
NA
Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein, PF-05212366,
Pfizer Inc, Pfizer Inc
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.
 
 
NCT06128733: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Active, not recruiting
1/2
1220
US
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadFi®, Meningococcal group B vaccine, Bexsero®, Trumenba®, Sanofi MenB, Menveo®, Placebo, MenABCYW conjugate vaccine, PENBRAYATM
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
06/25
06/25
2023-000924-13: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Not yet recruiting
1/2
1120
US
MenQuadfi, Bexsero, Trumenba, Menveo, 554, Suspension for injection, Solution for injection in vial, Suspension for injection in pre-filled syringe, Powder and solvent for solution for injection, MenQuadfi, Bexsero, Trumenba, MENVEO
Sanofi Pasteur Inc., Sanofi Pasteur Inc.
Bacterial infections and mycoses, Bacterial infections and mycoses, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04825223: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Terminated
1
576
US
Multicomponent Meningococcal B Vaccine, Trumenba®, Meningococcal Group B Vaccine MenB, MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Bexsero®, Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine, MenQuadfi™
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
07/22
07/22
NCT05873751: A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed
N/A
1307378
US
Trumenba Vaccine, MenACWY Vaccine
Pfizer
Gonorrhea, Chlamydia, Meningococcal Vaccines
03/24
03/24

Download Options